Letters to the Editor Pasquereau-Kotula E, Nigro G, Dingli F, Loew D, Poullet P, Xu Y, Kopetz S , Davis J, Peduto L, Robbe-Masselot C, Sansonetti P, Trieu-Cuot P, Dramsi S
By performing a GWAS in the tirzepatide-treated population alone (Supplementary Table 12), we identified an association between the vomiting side effect and GIPR (rs71338792, P = 4.2 10 9 , odds ratio = 1.84
What to do before starting to microdose GLP-1s Before starting the GLP-1 medication, consider the following: 1
Improved survival from acute renal failure after treatment with intravenous essential L-amino acids and glucose
A review of pivotal clinical trials for semaglutide (STEP, SUSTAIN), dulaglutide (REWIND), liraglutide (LEADER), and tirzepatide (SURPASS, SURMOUNT) does not identify muscle cramps as occurring at significantly higher rates compared to placebo groups